Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Follicular Lymphoma

Follicular Lymphoma

Part of Non-Hodgkin's Lymphoma

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Follicular Lymphoma

142 trials tracked for Follicular Lymphoma: 12 in phase 3 or 4 and 8 with published results. The most-cited published study has 364 citations.

142Trials tracked
12Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 1 Phase 3 11 Phase 2 105 Phase 1 14 Other / NA 11
  1. Phase 3 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma Completed · 364 cited
  2. Phase 3 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) Completed · 82 cited
  3. Phase 3 To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan Completed · 75 cited
  4. Phase 3 To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma Completed · 63 cited
  5. Phase 3 A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Completed · 43 cited
  6. Phase 3 Double Cord Versus Haploidentical (BMT CTN 1101) Completed · 10 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Completed · 9 cited
  2. Phase 3 Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma Completed
  3. Phase 4 An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma Completed
  4. Phase 3 A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma Completed
  5. Phase 3 Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma Completed
  6. Phase 3 A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma Completed
  7. Phase 2 A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Completed
  8. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  9. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  10. Phase 2 A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma Completed
  11. Phase 2 Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma Completed
  12. Phase 2 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed
  13. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  14. Phase 2 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Completed
  15. Phase 2 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Completed
  16. Phase 2 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Completed
  17. Phase 2 Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma Completed
  18. Phase 2 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Completed
  19. Phase 2 Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Completed
  20. Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  21. Phase 2 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Completed
  22. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  23. Phase 2 Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Completed
  24. Phase 2 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed
  25. Phase 2 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Completed
  26. Phase 2 Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma Completed
  27. Phase 2 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma Completed
  28. Phase 2 Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma Completed
  29. Phase 2 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed
  30. Phase 2 A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Completed
  31. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  32. Phase 2 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed
  33. Phase 2 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Completed
  34. Phase 2 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Completed
  35. Phase 2 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas Completed
  36. Phase 2 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Completed
  37. Phase 2 A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma Completed
  38. Phase 2 Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Completed
  39. Phase 2 Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma Completed
  40. Phase 2 Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma Completed
  41. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  42. Phase 2 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Completed
  43. Phase 2 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Completed
  44. Phase 2 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies Completed

Showing the 50 most-cited and recently-updated of 142 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Follicular Lymphoma: what the trials found

Ibrutinib demonstrated significant improvements in Progression-Free Survival (PFS) and Overall Response Rate (ORR) compared to the control arm, with p-values of 0.0231 and 0.0040 respectively 1. While Ibrutinib showed superior PFS and ORR, no statistically significant difference was observed in Overall Survival (OS) 1.

Several trials evaluated Rituximab and its biosimilar; these studies reported high response rates and stable outcomes, including a notable number of participants achieving treatment response at 13 weeks [15, 18] and established efficacy through various clinical endpoints [9, 16].

Other established interventions include Fludarabine [3, 7, 22], GP2013 (showing specific PFS data) 10, CT-P10 (reporting ORR at 7 months) 12, and PF-05280586 (demonstrating an ORR of 70.7% vs 75.5% with manageable Grade 3+ adverse events) 13.

Safety data for Obinutuzumab showed that the percentage of patients experiencing Grade 3 or higher infusion-related reactions (IRRs) was 0% when administered at a standard rate after an initial cycle without severe reactions 8. Haploidentical Bone Marrow Transplant showed no significant difference in PFS compared to control, but did show significantly higher rates of neutrophil recovery 14.

Recent results — preliminary, needs further review

  • Mosunetuzumab (Phase 2) 2
  • Lenalidomide (Phase 2) reported progression-free survival at 18 weeks and 2 years across multiple cohorts, with response rates reaching up to 100% in some groups 4.
  • BGB-10188 (Phase 2) 5
  • Axicabtagene ciloleucel (Phase 2) showed an ORR of 92% vs 69% and a CR rate of 78% vs 52%; among patients with 3 or more prior lines of therapy, the ORR was 91% vs 75% 6.
  • Nivolumab (Phase 2) 19

For the clinician treating this condition

  • Ibrutinib is established as effective for improving both Progression-Free Survival and Overall Response Rate in follicular lymphoma patients 1.
  • Axicabtagene ciloleucel shows high objective response rates, particularly in patients who have received three or more prior lines of therapy 6.
  • Obinutuzumab demonstrates a favorable safety profile regarding Grade 3+ infusion-related reactions when administered at standard rates 8.

AI synthesis of 11 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Oncology RCT
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Blood Jun 20, 2026
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma
Hematology Phase II
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma Subcutaneous Mosunetuzumab Shows Promise for Follicular Lymphoma Patients
This Phase 2 primary analysis evaluated fixed-duration subcutaneous mosunetuzumab versus mosunetuzumab IV in patients with relapsed or refra…
A Phase 2 trial found subcutaneous mosunetuzumab had lower rates of severe side effects than the IV version for treating follicular lymphoma…
May 1, 2026
Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients
Oncology Phase II
Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients New Drug Shrinks Stubborn Lymphoma Tumors After Other Treatments Fail
This single-arm, multi-center phase 2 study evaluated abexinostat in 90 patients with relapsed or refractory follicular lymphoma who had rec…
A new treatment is helping some patients with stubborn lymphoma shrink tumors and stay in control for over a year, even after other therapie…
Apr 27, 2026
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
Oncology Meta-analysis
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Apr 16, 2026
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Hematology RCT
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …
Apr 2, 2026

Research across Non-Hodgkin's Lymphoma

Related studies from across the Non-Hodgkin's Lymphoma family.

Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients
Oncology RCT
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients Nursing Program Reduces Fall Risk for Lymphoma Patients
This randomized controlled trial of 210 older adults with non-Hodgkin's lymphoma found that a multifaceted preventive nursing program signif…
A specialized nursing program significantly reduced falls and improved mobility for older adults undergoing chemotherapy for lymphoma.
Jul 20, 2026
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis
Oncology Meta-analysis
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis Gene Variants Linked to Higher Non-Hodgkin Lymphoma Risk
This meta-analysis of 53,864 cases and 60,448 controls found that certain IL-10 polymorphisms (rs1800890 and rs1800896) are associated with …
Certain IL-10 gene variants may slightly raise the risk of non-Hodgkin lymphoma, a large analysis finds.
Jul 4, 2026
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
Oncology Meta-analysis
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Jul 3, 2026
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Nutrition & Obesity Medicine Meta-analysis
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Frontiers Jun 24, 2026
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
Allergy & Immunology Meta-analysis
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Frontiers Jun 23, 2026
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Oncology RCT
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Jun 20, 2026
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
Allergy & Immunology Meta-analysis
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs Organ transplant recipients face higher risk of certain cancers
This meta-analysis of multi-centre cohort and registry-based studies indicates that solid organ transplant recipients experience significant…
People who receive heart or lung transplants face a significantly higher risk of dying from specific types of cancer.
Frontiers Jun 20, 2026
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Hematology Sys. Review
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Frontiers Jun 10, 2026
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Oncology Sys. Review
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Frontiers Jun 2, 2026
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Hematology Meta-analysis
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Jun 1, 2026
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
Allergy & Immunology Sys. Review
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Frontiers May 29, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026

Questions about Follicular Lymphoma

What are the safety results for fixed-duration subcutaneous mosunetuzumab in Follicular Lymphoma?

Fixed-duration subcutaneous mosunetuzumab shows a favorable safety profile with lower rates of severe immune-related adverse events compared to the intravenous version in relapsed follicular lymphoma.

Full answer →
Does adding R-CVP after radiotherapy improve survival for early-stage Follicular Lymphoma?

Adding R-CVP after radiotherapy significantly improves progression-free survival in early-stage follicular lymphoma, but overall survival benefit is not yet proven.

Full answer →
Do new therapies help Follicular Lymphoma patients who progress within 24 months?

Yes, new therapies like CAR T cells, bispecific antibodies, and targeted drugs show high response rates in follicular lymphoma patients who progress within 24 months.

Full answer →
What is the response rate for abexinostat in relapsed Follicular Lymphoma?

Abexinostat shows a 69.5% objective response rate in relapsed follicular lymphoma, based on a phase 2 trial.

Full answer →
Can Revlimid be used to treat Follicular Lymphoma?

Yes, Revlimid (lenalidomide) is FDA-approved for previously treated follicular lymphoma, specifically in combination with rituximab.

Full answer →
See all 5 questions about Follicular Lymphoma →